Trial site
Memorial Antalya Hospital
Antalya, 07090, TürkiyeNot linked to an institution yet
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 24 trials
- Status
- Recruiting6 trials
- Active, not recruiting4 trials
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Eli Lilly and Company2 trials
- BioNTech SE1 trial
- Hoffmann-La Roche1 trial
- Loxo Oncology, Inc.1 trial
Running trials
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441· Phase 2· Janssen Research & Development, LLC· Source
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
NCT06841055· Phase 2· BioNTech SE· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478· Phase 2· Loxo Oncology, Inc.· Source
Contact: Fatih Demirkan (principal investigator)
Recruiting
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
NCT06750094· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581· Phase 3· Eli Lilly and Company· Source
Contact: Mustafa Ozdogan (principal investigator)
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT04819100· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
NCT04576455· Phase 2· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error